(Göteborg, 2 mars 2021)
In the treatment of severe obesity, medication can help with weight loss and complement changes in daily health habits. Pharmaceutical company Navamedic has launched a patient support programme in Sweden, with Oriola as a partner, targeting patients who have a specific medication to support weight loss. Individual support is especially important during the first few weeks of the treatment.
Obesity is one of the major health problems impacting both people’s quality of life and healthcare costs, as it increases risks for several chronic diseases. According to the Public Health Agency of Sweden, around 50% of adults in the country are overweight or obese, and obesity is among the top five risk factors for losing healthy years of life.*
The primary treatments of obesity are changes in daily habits related to, for example, nutrition and physical activity. For patients with severe obesity, treatment might be a combination of changing habits, medication and even surgery. To support both people and the healthcare system in obesity treatment, Navamedic has developed a unique support concept for the Nordics. The programme was first launched in Sweden in October 2020, and it combines support materials with individual guidance for patients who have medication to assist with weight loss.
“Our digital support platform contains, for example, information about behavioural change, social and environmental challenges, nutritional planning as well as a tool for building and maintaining healthy habits. The support programme is available for free after registration. People with medication can also contact nurses through the platform to have individual guidance,” says Alexander Lidmejer, Commercial Director Specialty Pharma at Navamedic.
Phone support and collaboration
In general, medication is an option for patients with a body mass index (BMI) of 30 or above, or who have a high BMI and other health risks or diseases, such as a high blood pressure or diabetes.
“Our nurses offer the patients individual support by phone, which is particularly important in the first few weeks. This is to motivate patients to commit to their treatment, but also to support them in making healthier choices in daily life and changing health-related habits, depending on their needs,” says Sara Fredriksson, Head of Patient Support Programmes at Oriola.
In addition to patient support services, Oriola’s Kronans Apotek pharmacies have an important role in informing patients about the support available when they come to a pharmacy to collect their prescription.
You can visit Navamedic’s ‘MyControl’ platform at: www.mycontrolsupport.se (in Swedish)
*Source: The Public Health Agency of Sweden’s website
For further information, please contact:
Alexander Lidmejer
Commercial Director Specialty Pharma
Navamedic
alexander.lidmejer@navamedic.com
Andreas Rosenlund
Public Affairs Director
Oriola
andreas.rosenlund@oriola.com
About Navamedic
Navamedic ASA is a Nordic pharma company and a reliable supplier of high-quality products, delivered to hospitals and through pharmacies, meeting the specific medical needs of patients and consumers. Navamedic is present in all Nordic countries, the Baltics and Benelux and has sales of specific products even in other European countries like UK and Greece. Our headquarter is in Oslo, Norway and we are listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com
About Oriola
Oriola is a health and wellbeing company operating in the Nordic countries. We help people to lead healthier lives by giving them access to sustainable health and wellbeing products and services. In Sweden, Oriola owns the country’s third-largest pharmacy chain, Kronans Apotek. In addition to pharmacies, our dose-dispensing, medical information and patient support services enhance the safety and effectiveness of pharmaceutical care. Our expert services support pharmaceutical companies throughout the entire lifecycle of medicines. Oriola’s supply chain ensures reliable and safe delivery of pharmaceuticals to pharmacies, hospital pharmacies, veterinarians and other healthcare operators. In 2020, Oriola Corporation’s net sales were 1.8 billion euros and we employed approximately 4,300 professionals. Oriola Corporation is listed on Nasdaq Helsinki. www.oriola.com